Amgen Q1 revenues up 6% to $6.2B; Non-GAAP EPS $4.25, +15%; reaffirms 2022 guide

AMGEN INC

2022-Q1 EPS reported $2.68 revenue$6,238,000,000

Total revenues $6.2B (+6% YoY); product sales grew 2% with double-digit volume growth for Repatha, Prolia, EVENITY.
GAAP EPS $2.68 (-5%); Non-GAAP EPS $4.25 (+15%) on revenue growth and lower share count.
GAAP operating income $2.5B (+17%); Non-GAAP operating margin 54.8% (+3.6 ppts).
Free cash flow $2.0B vs $1.9B in Q1 2021.
2022 guidance: revenue $25.4-26.5B; GAAP EPS $12.53-13.58; Non-GAAP EPS $17-18 reaffirmed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.